Sun Pharmaceutical Aims To Keep Rivals In The Rearview Mirror
This article was originally published in PharmAsia News
India’s Sun Pharmaceuticals says it is set to keep sales volumes growing in part through an aggressive acquisition strategy and a more diversified mix of products after third quarter profit more than quadruples.
You may also be interested in...
FDA is allowing Sun Pharma Global FZE to import its unapproved liposomal version of doxorubicin, Lipodox, to alleviate a shortage, but has not yet given the drug full approval.
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.